![ZyVersa Therapeutics](https://gocience.com/logos/new/dc79419d9476b2831c09870e48344c79f486d7a01898ae5a207f12f1b89ab045.jpg)
Zy Versa Therapeutics
Pharmaceuticals, 2200 N Commerce Pkwy, Weston, Florida, 33326, United States, 11-50 Employees
Phone Number: 75********
Who is ZYVERSA THERAPEUTICS
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging two licensed proprietary product platforms to develop pharmaceutical products that address unmet ...
Read More
![map](/x-assets/maps1.0-950f22e3512fa69a51fdf6612dcb593a74c2f8790b6e4ec5601cebb82b592ab9.png)
-
Headquarters: 2200 N Commerce Pkwy, Weston, Florida, 33326, United States
-
Date Founded: 2014
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
-
CEO: Steve Glover
Industry: Pharmaceuticals
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from ZYVERSA THERAPEUTICS
ZyVersa Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding ZyVersa Therapeutics
Answer: ZyVersa Therapeutics's headquarters are located at 2200 N Commerce Pkwy, Weston, Florida, 33326, United States
Answer: ZyVersa Therapeutics's phone number is 75********
Answer: ZyVersa Therapeutics's official website is https://zyversa.com
Answer: ZyVersa Therapeutics's revenue is $5 Million to $10 Million
Answer: ZyVersa Therapeutics's SIC: 2834
Answer: ZyVersa Therapeutics has 11-50 employees
Answer: ZyVersa Therapeutics is in Pharmaceuticals
Answer: ZyVersa Therapeutics contact info: Phone number: 75******** Website: https://zyversa.com
Answer: ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging two licensed proprietary product platforms to develop pharmaceutical products that address unmet medical needs in the areas of renal and inflammatory diseases. Lead renal candidate, Phase 2a-ready VAR 200, mediates removal of excess intracellular lipids in the kidneys filtration system that contribute to kidney damage leading to end-stage kidney disease. Lead anti-inflammatory drug candidate, inflammasome ASC inhibitor (IC 100), blocks initiation and perpetuation of damaging inflammation thats pathogenic in a multitude of inflammatory diseases.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
CEO at ZyVersa Therapeutics
Sign in to CIENCE GO Data to uncover contact details
Free credits every month